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Abstract: Photodynamic inactivation of microorganisms has gained substantial attention due to its
unique mode of action, in which pathogens are unable to generate resistance, and due to the fact
that it can be applied in a minimally invasive manner. In photodynamic therapy (PDT), a non-toxic
photosensitizer (PS) is activated by a specific wavelength of light and generates highly cytotoxic
reactive oxygen species (ROS) such as superoxide (O2−, type-I mechanism) or singlet oxygen (1O2*,
type-II mechanism). Although it offers many advantages over conventional treatment methods,
ROS-mediated microbial killing is often faced with the issues of accessibility, poor selectivity and
off-target damage. Thus, several strategies have been employed to develop target-specific antimicrobial
PDT (aPDT). This includes conjugation of known PS building-blocks to either non-specific cationic
moieties or target-specific antibiotics and antimicrobial peptides, or combining them with targeting
nanomaterials. In this review, we summarise these general strategies and related challenges,
and highlight recent developments in targeted aPDT.
Keywords: photodynamic therapy; photosensitizer; reactive oxygen species; antimicrobial resistance;
nanomaterials; antimicrobial peptides
1. Introduction
The revolutionary discovery and mass production of penicillin in the first half of the 20th century
opened a new era in the fight against bacterial infections [1,2], and the development of new antibiotics in
the following decades reduced considerably the mortality caused by infectious diseases. Unfortunately,
as antibiotics began to be considered as a quick and easy fix to infections, their misuse and abuse have led
to the generation of wide-spread antimicrobial resistance (AMR) [3], and, according to a World Health
Organization’s (WHO) report [4], the golden era of antibiotics is now coming to an end. Based on the
WHO’s estimations, approximately 700,000 deaths are caused by multi-drug resistant (MDR) infections
every year. Similar assessments state that this number could reach 10 million by 2050 if no action is
taken, which makes research for alternative treatments a vital mission. As bacteria reproduce rapidly
and transfer genetic material (often driven through environmental stresses), mutations responsible for
resistance mechanisms spread quickly throughout the microbial world and alarming levels of resistance
have already been reached. Thus, new therapies immune to resistance are of utmost importance [5,6].
Photodynamic therapy (PDT) utilises a chromophore, typically called a photosensitizer (PS),
which is able to “sensitise” the surrounding triplet oxygen upon absorption of light, and produce highly
reactive oxygen species (ROS) such as hydroxyl radicals (Type I photo-process) and cytotoxic singlet
oxygen (Type II photo-process) [7–10]. Initially used for the treatment of cancer [11–14], skin [15]
or dental diseases [16], the increase in AMR has drawn the focus of the scientific community to the
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adaptation of PDT for the treatment of infections [17–21]. Antimicrobial PDT (aPDT) has become a
prominent alternative to classic antibiotic treatment thanks to outstanding advantages such as the
non-invasive nature of light, ease of application, and above all the absence of possible resistance
to ROS in microorganisms [22]. Thus, the application of PDT has extended to virtually all types of
pathogens, including bacteria [17–21], fungi [23–25], viruses [26,27] and parasites [28,29]. In particular,
following the major concerns around MDR bacteria, several new PS have been tested, adapted or
developed for aPDT [30]. In this sense, positively charged PS appear promising for aPDT as they
can interact electrostatically with the negatively charged bacterial membrane, and the synthesis of
several PS functionalised with small cationic functional groups has been reported [31–35]. Nonetheless,
two main concerns can arise from this strategy: (i) a poor target selectivity since such cationic species,
due to electrostatic interactions with mammalian cells, lead to off-target damage, and (ii) the poor
efficiency of aPDT against a certain type of pathogens, in particular Gram− bacteria and biofilms.
While Gram+ bacteria are also the cause of serious infectious diseases, more than 90% of Gram− bacteria
are considered pathogenic, and since their membrane composition is such that many antibacterial
agents simply fail to enter (vide infra), they represent a major threat. Because of these selectivity issues
and potential side-effects, and in contrast to the use of PDT in oncology, aPDT has yet to translate
widely into clinics [36–40].
In this context, current challenges are focused on an improvement of both the selectivity of
PS molecules towards microorganisms, and of their efficiency. Generally, this can be achieved by
enhancing the affinity of the PS for specific bacterial components (i.e., membrane proteins etc.), or by
disturbing the pathogen to increase its uptake. Practically, known PS building blocks have been
co-administered, vectorised or conjugated in a number of different ways so as to incorporate either
poly-cationic materials, bacterial-targeting peptides, polymers, antibiotics or antibodies fulfilling either
passive or active targeting roles [41–44]. The synthesis of covalent peptide- or antibiotic-PS conjugates
is perhaps the most straightforward way to reach this goal, but supramolecular and nano-approaches
have also led to important photo-antimicrobial nanomaterials. In this review, we aim to present the key
concepts and underlying challenges in aPDT, with a focus on the most recent work over the past five
years in the rapidly expanding field of PS conjugates and PS-containing nanoparticles (NPs). We stress
that the focus here is on the photodynamic treatment of infectious diseases, but invite the reader to
explore other key applications such as self-disinfecting materials and fabrics [45,46].
2. Mechanisms and Challenges in aPDT
2.1. Photophysical Principles of PDT
Photodynamic therapy requires three major components: a PS, molecular oxygen (3O2), and light.
The concept is based on the electronic properties of molecular oxygen which naturally resides in
a triplet ground state and can therefore interact with triplet-state chromophores. Thus irradiation
of a PS by a resonant wavelength of light will excite an electron from ground state 0PS to a singlet
excited state 1PS*, which then undergoes inter-system crossing (ISC) to form a relatively long-lived
triplet state 3PS*. The efficiency of the ISC process and lifetime of 3PS* are two key parameters of a
good PS, as this triplet state enables the generation of ROS via Type-I and Type-II photo-processes
(Figure 1) [8,10,47]. The Type-I photo-process involves electron transfer between 3PS* and a substrate
(in a PDT context, generally a biomolecule) to generate a radical anion 3PS.− which then interacts with
ground-state molecular oxygen (3O2) to form a superoxide radical (O2.−). This radical-anion further
reacts to generate other ROS following the Haber–Weiss reaction [8,10,47]. In the Type-II mechanism,
a triplet-triplet energy transfer occurs between 3PS* and 3O2 to generate singlet molecular oxygen
(1O2*), a short-lived and highly cytotoxic species (energetically the 3O2 to 1O2* transition requires
94.3 kJ.mol−1). The Type-II photo-process is generally the most common, and its overall photophysical
efficiency is expressed in the form of a “singlet oxygen quantum yield” Φ∆, which is a function of
the ISC rate constant, the probability of quenching by molecular oxygen, and the efficiency of the
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triplet-triplet energy transfer. Ultimately, Φ∆ is best expressed as a percentage, and represents the
number of 1O2* molecules generated for 100 photons absorbed.
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Figure 1. Simplified Jabłoński diagram showing the generation of reactive oxygen species (ROS) by a
photosensitizer (PS) following absorption of light, intersystem crossing and Type-I and -II mechanisms.
In antimicrobial photodynamic therapy (aPDT), the resulting ROS are able to kill bacteria and fungi as
illustrated on the right.
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Thus the properties of many different PDT dyes have been well documented, while many families
of compounds have been used to eradicate bacterial species (Figure 2). However, achieving high
specificity of treatment while retaining the other criteria is a challenge for aPDT.
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Many strategies rely on the electrostatic interaction of the dye with various cell membrane
components of the microorganisms (Figure 2). For instance, Gram+ bacteria have a cell membrane
composed mainly of a phospholipidic bilayer and peptidoglycans, respectively rich in phosphate and
hydroxyl groups, and which, at physiological pH, carry a high density of negative charge, making them
susceptible to targeting with cationic PS.
As such it is commonly accepted that cationic PS such as methylene blue (MB) [49], toluidine blue
O (TBO) [50] and other phenothiazinium derivatives [51], or cationic porphyrins [52,53] and
phthalocyanines (Pc) [54] are well adapted to aPDT, showing both better efficiency and selectivity than
neutral [55,56] or negatively-charged sensitisers [57–60] (Figure 2). Some other synthetic PS decorated
with cationic groups to target bacterial infections include BODIPY [31,44,61], perinaphthenone [62]
or perylene [35] derivatives. Anionic and neutral PS generally need to be chemically modified or
vectorised to eliminate electrostatic repulsion with the bacterial membrane before use in aPDT.
Light-induced inactivation of pathogens has proven more effective on Gram+ bacteria due to their
“single-layered” cell wall/membrane structure that allows deeper penetration of the PS (Figure 3). Thus,
whilst aPDT of Gram+ bacteria can be achieved by even mono-cationic PS, poly-cationic derivatives
are usually required for the eradication of Gram− bacteria. The presence of a well-organised and thick
outer membrane in Gram− bacteria makes them more resistant to aPDT [43] and the thickness of the
outer membrane limits the penetration of PS through the cell membrane and wall. This highlights the
necessity to design specific sensitisers against such pathogens.
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to this strategy and more difficult to treat with aPDT. Finally, both types of pathogens are known
to generate biofilms in which an extracellular polymer matrix (EPM) protects colonies from outside
“aggressions”. Moreover, biofilms are known to be highly pathogenic and hard to treat because of poor
drug penetration while displaying a 100- to 1000-fold increase in minimum inhibition concentrations
of many drugs [64]. Because of this, more advanced structural modifications are often required,
which involves the conjugation of the PS with “passively” targeting poly-cationic or antimicrobial
materials, or with “actively” targeting pathogen-specific antimicrobial peptides (AMPs), or antibiotics
(Figure 3), as will be discussed in the following sections.
3. Recent Studies on Targeted aPDT
3.1. Small Molecules & Peptide Conjugates
3.1.1. Conjugation of Small Cationic Groups for Electrostatic Interactions
The development of cationic PS increasing the electrostatic interactions with bacterial surface
components (e.g., lipoteichoic acid (LTA) and lipopolysaccharide (LPS) [65]) is a well-known
straightforward approach and has been applied for decades [51,53,66]. Porphyrin, Pc, and both
their extended and reduced derivatives have been extensively studied and conjugated to different
amino-functionalised moieties [53,67]. Building on this approach, a meso-substituted porphyrin
derivative bearing four cationic amino groups was developed by Mamone et al. [32] and successfully
eradicated Gram+ and Gram− bacteria in both planktonic culture and biofilm models. Interestingly,
Li et al. reported a comparative study to investigate the effects of charge on aPDT activity using two
poly-cationic zinc-phthalocyanines (ZnPc) conjugated to mono- and di-amino moieties (formal charges
of +4, +8) against the Gram− bacteria E. coli. As expected, the more highly charged ZnPc derivatives
exhibited better inactivation efficacy [33].
Basic aminoacid residues (i.e. arginine, lysine and histidine) have the potential to target the
negatively charged bacteria surface (Figure 4a). Meng et al. investigated the conjugation of porphyrins
to all three basic aminoacids, and investigated their aPDT efficiency [68]. The lysine-porphyrin
conjugate was reported to effectively eradicate clinical isolates of bacterial strains including MRSA,
E. coli, and P. aeruginosa both in vivo and in vitro [68,69]. Logically, peptides, containing such building
blocks, have been used to take the approach further. Indeed peptide-based strategies offer significant
advantages in which the cationic charge can be readily tuned by varying the number of amino
acids. The fine-tuning of the hydrophilic/hydrophobic properties and length of the peptide can
enhance pathogen selectivity over mammalian cells while enhancing the solubility of aromatic PS dyes.
A significant example of this rationale was reported by Zhou et al. [70] with a hepta-arginine peptide
functionalised at the C-terminus with the hydrophobic purpurin-18 PS (Figure 4b). This probe selectively
bound to Gram+ bacteria via electrostatic and hydrophobic interactions, and upon illumination led to
complete eradication of Gram+ bacteria. However, the survival rate of Gram− bacteria was high even at
high concentrations, presumably due to their thicker cell wall preventing contact of the cell membrane
with the PS. In a similar way, Zhao et al. used the membrane binding affinity of arginine-based peptides
and developed another probe for aPDT [71] (Figure 4c). They investigated the effect of the number
of arginines, substituted axially on a silicon(IV) phthalocyanine (SiPc) PS, on the binding and PDT
potency against microbes. Among all the synthesised Arg-SiPc derivatives, the tri-Arg substituted
probe showed the highest cellular uptake (strong electrostatic interactions) and phototoxicity against
Gram+ and Gram− bacteria as well as fungi in in vitro experiments. In addition, they showed the
in vivo therapeutic applicability of this approach with the treatment of S. aureus infection in mice
models. Importantly, the probe photodynamically inactivated all pathogens with lower IC90 values
than the FDA approved photosensitizer MB. Poly-lysine is another well-known type of conjugate in this
sense [72], however, poly-cationic PSs can prove toxic to mammalian cells such that the translational
potential of such probes can be limited. For this reason, more specific targeting molecules have been
used for enhanced uptake and binding to bacteria, with selective agents such as antibiotics.
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aggregation-induced enhanced emission (AIEE) properties. This theranostic probe allowed selective
visualisation and eradication of both vancomycin sensitive and resistant Gram+ bacteria [89]. Zhai and
Wang conjugated a tetrakis(p-aminophenyl)porphyrin to vancomycin and investigated its aPDT activity
against six Gram+ bacteria strains including vancomycin-resistant E. faecalis (VRE) [90]. The designed
probe showed high selectivity with varying eradication efficacies towards all Gram+ strains. In contrast,
a library of photoactive multi-cationic PDT agent was synthesised by Huang et al. [91], and surprisingly,
the vancomycin conjugate demonstrated the lowest aPDT activity among all probes. This low efficacy
may be the result of a reduced binding affinity of vancomycin due to the conjugation of this multi-cationic
bulky PS. Another possible explanation resides in the loss of planarity in the π-conjugated system of
the PS sub-unit resulting from its attachment to such a bulky antibiotic, which decreases the extinction
coefficient, and therefore the ROS generation efficiency of the probe. Hence, this study reveals the
importance of the design of the probe (PS, antibiotic, and spacer), from a chemical, biological and
photophysical point of view, to achieve highly efficient aPDT activities.
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3.1.3. Antimicrobial Peptide Conjugates
Antimicrobial peptides (AMPs) are linear or cyclic amphipathic peptides that exert a bacteriostatic
or bactericidal activity via targeting of the cell membranes of bacteria by electrostatic interactions,
and disruption of membrane integrity by insertion, and/or disturbing of intracellular functions [92,93].
More than 2500 AMPs have been reported to date [94] and several of them are used clinically,
including for the treatment of MDR infections. As such new targeted aPDT probes have taken advantage
of their hybrid interactions, using both electrostatic interactions and membrane anchoring/disrupting
capacities, to increase the efficiency of the PS dyes [95]. In a covalent conjugation strategy,
decorating AMPs with PS units has attracted substantial attention in the field of aPDT.
Polymyxins (PMX) are non-ribosomal lipopeptide antibiotics of the AMP family used for
the treatment of infections caused by Gram− bacteria [96,97]. Their structure is composed of a
cyclic hepta-peptide, a tripeptide side chain and hydrophobic tail. Based on the variations of
the amino acid sequence at the 6th position on the hepta-peptide, the AMP is denominated as
polymyxin-B (D-phenylalanine) or polymyxin-E, also known as colistin (D-leucine). As for many
AMPs, the antibacterial mechanism relies on their amphiphilic character, with electrostatic interactions
and membrane insertion—leading to entropically enhanced binding. Indeed, the protonated γ-amino
units (diaminobutyric acid, Dab) in the cyclic hepta-peptide bind to the outer membrane of bacteria
mainly including the negatively charged LPSs. In a second step, the hydrophobic fatty acid tail and
D-Phe and D-Leu residues in the cyclic hepta-peptide insert into the outer membrane. This dual mode
of action disrupts the cell membrane structure and leads to cell lysis. PMX derivatives are now widely
used as last-resort treatment of Gram− infections, and this popularity has led to several examples of
conjugation with photoactive molecules (Figure 5).
In this sense, the very first example of aPDT was a synergistic co-administration of PMX with
porphyrins reported by Nitzan et al. in 1992 for the photo-inactivation of Gram− bacteria [95].
This non-covalent approach proved that AMPs can be used to increase membrane permeability in
the targeted microorganisms and increase PS uptake, a strategy that is still used to this day [98].
In more recent years, Le Guern et al. made substantial efforts to develop photoactive PMX-PS
covalent conjugates using the PMX-B scaffold as targeting unit [99–101]. A cationic porphyrin was
attached to a cysteine-modified PMX-B derivative using thiol-maleimide click chemistry, and the
probe exhibited enhanced aPDT efficacy against S. aureus, P. aeruginosa and E. coli compared to the
porphyrin alone. Nonetheless, a loss of selectivity was observed, possibly due to the reversible nature
of the thiol-maleimide chemistry or the nature of the poly-cationic compounds. In addition, the probe
showed dark toxicity with low minimum bactericidal concentrations (MBC) (P. aeruginosa (10 µM) and
E. coli (1.2–5.0 µM)), which presumably arises from the bactericidal property of the PMX-B. To diminish
this effect, the diaminobutyric acid (Dab) units were replaced with lysines [101], which showed reduced
bactericidal activity while maintaining a high aPDT efficacy against both Gram+ and Gram− bacteria.
Building on PMX’s selectivity, Bayat and Karimi generated a targeting tri-branched aPDT probe
bearing three colistin (PMX-E) moieties covalently attached to a Zinc phthalocyanine (ZnPc) via
random imine formation [102]. To enhance the solubility of this poorly soluble ZnPc-Col probe,
it was incorporated, along with glutaraldehyde in different ratios into a chitosan-based hydrogel
system (see Section 3.2.2 for more chitosan-based systems). The ZnPc-Col PS embedded into
the hydrogels demonstrated variable singlet oxygen efficacies; i.e., the hydrogels with the lowest
glutaraldehyde content produced the highest 1O2* efficiency due to the fast release of ZnPc-Col.
This hydrogel strategy allowed the eradication of Gram− P. aeruginosa more effectively than the
control (ZnPc-glutaraldehyde hydrogel) due to the enhanced solubility of the probe, and increased
permeabilisation of the bacteria membrane.
Following the above studies, we developed an aPDT probe based on the MB and PMX-B
sub-units as a part of our ongoing studies on the development of diagnostic and theranostic agents
for bacterial infections [103,104]. Most of the above-mentioned aPDT applications were performed
against planktonic bacteria. However, the vast majority of infections are associated with biofilms
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in which the extracellular polymer substances (EPS) provide extra resistance against penetration of
antibiotics. In our design, the hydrophobic tail of PMX-B was replaced with a short polyethylene glycol
(PEG) linker and attached to a PS (MB) using amine-NHS ester coupling chemistry [104] (Figure 6).
In contrast to other studies constructed on the PMX scaffold, the probe exhibited reduced dark
toxicity (diminished antibiotic activity) while preserving high Gram− bacteria selectivity (E. coli and
P. aeruginosa). In addition to its selectivity, the probe showed outstanding photodynamic bactericidal
activity by achieving complete killing of Gram− bacteria in all models including planktonic bacteria,
infected skin model, and most importantly biofilms. Furthermore, the absence of detrimental effect
on human erythrocytes makes it a significant candidate to treat Gram− bacterial infections without
triggering serious side effects.
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protoporphyrin IX (PpIX) as a PS [107] (Figure 7). The probe showed excellent photodynamic activity 
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i re 6. Ill strati f t e tar ete a treat e t f ra acteria it t e l xi s ( )-
ethylene blue (MB) conjugate, during which the PMX cyclopeptide binds to the pathogen membrane
and ROS are generated once the light is switched on—an example of entropically driven aPDT.
Other significant examples of this approach were reported with the peptide (KLAKLAK)2,
a prototypical AMP with MIC values in the µM range for E. coli, P. aeruginosa, and S. aureus.
Conjugation of this AMP to Eosin Y was successfully reported by Johnson et al. in order to counter the
high hydrophilicity and poor membrane affinity of this anionic PS, and actively target Gram+ and
Gram− bacteria while retaining good selectivity towards mammalian cells [105]. It is worth mentioning
that, recently, Costley et al. reported an RB-AMP conjugate using the same targeting peptide for
applications in antibacterial sonodynamic therapy (aSDT) using high-intensity focused ultrasounds
as trigger [106]. Cheng et al. also designed a probe composed of this AMP using protoporphyrin
IX (PpIX) as a PS [107] (Figure 7). The probe showed excellent photodynamic activity against both
Gram+ (S. aureus) and Gram− (E. coli) bacteria in in vitro experiments. Its high inactivation efficacy
relies on both the hydrophobic/hydrophilic structure of peptide and the ROS generation ability of the
PS. The AMP unit enables the formation of a α-helical structure that positions the positive charges
on one side and leads to strong interactions between the dye and both bacteria surfaces. After initial
electrostatic interactions, the AMP-PS conjugates can penetrate into the cell membrane and disrupt
cell integrity, while light irradiation at longer wavelength leads to oxidation of biomolecules (e.g.,
nucleic acids) thus resulting in bacterial killing. As in the above example, the chimeric peptide also
eradicated Gram+ bacteria (S. aureus) in infected mice models.
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been reported over the last two decades for the treatment of infectious diseases. This section will 
present the different types of macromolecules and nanomedicines used in aPDT over the last 5 years, 
with a focus on the carriers that passively or actively increase bacterial uptake. 
3.2.1. Micelles and Liposomes 
Liposomal and micellar formulations are among the most extensively studied nanostructures 
for biomedical applications. Their structures allow encapsulation of lipophilic drugs in the core of 
micelles and the membrane of liposomes, or hydrophilic molecules in the core of liposomes. 
Figure 7. Examples of aPDT probes based on the AMP sequences (KLAKLAK)2 and Apidaecin 1b
conjugated to different photosensitizing units.
Other peptide sequences like Apidaecin 1b [42,108] (Figure 7) or Aurein 1.2 [109] have been
used i covale t r non-covalent strategies leading to notable examples of aPDT. In addition to the
strat ies prese ted in this section, covalent and non-c valent approaches can also be expl ited
and compleme ted with the use of nanomaterials acting as platforms, matrixes or delivery vehicles,
thus yielding macro- or nano-photos sitizers with special fe tures for aPDT.
3.2. Macro- and Nano-Photosensitizers
In addition to selectivity issues, many PS have poor solub lities and/or have a tendency to
self-aggregate in no -photoactive forms, thus impeding ROS or 1O2* production. Covalent conjugation
o pept des and antibiotics can improve this, but this sometimes ecessitates long and cost y sy th sis,
without guaranteeing high efficiency for clinically relevant conditions ( .e., b ofilms or MDR strains).
In this sen e, macr - and na o-PS ca offer advantages over free PS, op ning access o different type
of m terials (including biomaterials and biomimetic stra egies), tec niques, and delivery st ategies.
Indeed, these structures ca act as vehicles with an inherently high PS loading. The local increase in
ROS production caused by his high concent ation of PDT drugs can improv th ir killing efficiency,
whil the incorporation of dyes within a nanoplatform can also increase resistance to p otobleaching,
and often pr vide access to an easier functionalisatio . This often relies either on supramolecular
interactions to construct nano-sized vehicles in which the PDT drug is “encapsulated” [46,110], or on
the covalent attachment of the PS on the surface of a nanomaterial [46]. This strategy has been
extensively applied in PDT for cancer treatment, but many nano-PS have also been reported over the
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last two decades for the treatment of infectious diseases. This section will present the different types of
macromolecules and nanomedicines used in aPDT over the last 5 years, with a focus on the carriers
that passively or actively increase bacterial uptake.
3.2.1. Micelles and Liposomes
Liposomal and micellar formulations are among the most extensively studied nanostructures
for biomedical applications. Their structures allow encapsulation of lipophilic drugs in the core of
micelles and the membrane of liposomes, or hydrophilic molecules in the core of liposomes. Therefore,
such nano-carriers present a high degree of versatility, potentially high PS loading and tuning of the
surface properties to enhance bacterial wall targeting and penetration, for instance by shielding the PS
and improving the cationic character of the surface layer.
Encapsulating aromatic compounds such as PS into micelles and liposomal structures has
been shown to enhance the photophysical properties of the dyes, with singlet oxygen escaping the
membranes of the carrier by diffusion [111]. This has been evidenced notably in micellar and liposomal
formulations of hematoporphyrins, in which encapsulation of the PS inside the hydrophobic region of
the NPs prevented the formation of photo-inactive aggregates [112]. More recently, Sharma et al. also
developed an innovative encapsulation system for MB and RB dyes in which the components of the
nano-carrier participate in the overall photophysical process [113]. Self-assembly of a copper-based
cationic metallo-surfactant and of an anionic surfactant allowed the preparation of either cation-rich or
anion-rich vesicles, suitable for encapsulation of anionic RB or cationic MB respectively. In such NPs
it was shown that the copper-based surfactant accelerated the ISC process towards the triplet state,
which enhanced the singlet oxygen generation of the PS. Efficient killing of MDR S. aureus was reported
with this nano-carrier, which was also reported as toxic to bacteria in the dark. Liposomes have
also been used extensively in the past to improve the efficacy of PS by disrupting the bacterial
cell-wall upon contact with the carriers. This strategy has been shown to enhance the uptake of
the PS and therefore the killing efficiency, even in the case of resistant strains [114]. In this sense,
and because of their strong tendency to self-aggregate which reduces both photophysical efficiency and
availability, the encapsulation of porphyrin-type PSs has been extensively studied for the treatment of
bacterial [114,115] and fungal infections [116].
In certain cases, tuning the building-blocks of the carrier can introduce additional targeting
properties to the NPs. This can be exemplified in the work by Liu et al. on the encapsulation of
Ce6 inside pH-responsive polymeric NPs [117]. The amino-functionalised polymer used for the
preparation of the liposomes was designed to be protonated in weakly acidic media such as urinary
tract infections environments. As a result, the Ce6-containing polymeric nano-carriers were able to
recognise and accumulate on the surface of bacteria via electrostatic interactions at the location of
the infection (Figure 8a). This charge-conversion system was able to kill efficiently both Gram− and
Gram+ bacteria with MIC values two times lower than the free PS. Cationic liposomes have also been
used for the encapsulation of MB, another PS with a tendency to dimerization [118]. A formulation
of cholesterol, zwitterionic and cationic lipids gave rise to liposomal structures in which MB would
assemble preferentially as a dimer thanks to its high loading, and therefore favour type-I ROS-mediated
photo-inactivation of bacteria (Figure 8b). The cationic lipid (DODAC) was employed to test the
correlation between the electrostatic interactions with negatively charged bacterial membranes and the
overall antibacterial efficacy of the compounds. Importantly, this system showed enhanced penetration
in E. coli biofilms, and reduced the inflammatory response due to LPS exposure to mammalian cells.
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A potential downside of cationic liposomes is their easy fusion with mammalian cell 
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medicine was reported by Morgado et al. for the treatment of fungal infections [120]. Their AlPc-
loaded nano-emulsion allowed the treatment of onychomycosis without local or systemic side-
effects. 
3.2.2. Bio-Sourced Oligosaccharide Conjugates 
In the world of NPs, bio-sourced macromolecules such as oligosaccharides represent a source of 
well-documented readily available building blocks for the elaboration of stimulus-responsive nano-
systems. Exploiting the properties (charge, supramolecular interactions, functionalisation, etc.) of 
oligosaccharides has given rise to numerous examples of nano-PS for aPDT. Their preparation relies 
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Chitosan is a bio-polymer obtained through deacetylation of chitin. Thanks to its intrinsic poly-
cationic nature, it has been reported to interact with the negatively charged phospholipids [121,122], 
which provides it with a broad-spectrum antibacterial and antifungal action, including the 
prevention of the development of biofilms [123]. Therefore, poly-cationic chitosan has been one of 
the most widely utilised delivery and uptake increasing nano-carriers in aPDT. 
Early examples of the potentiation of PDT by chitosan goes back to the 2000s, and it has since 
then been used in co-administration, nano-formulations or covalent attachment of the xanthene 
derivatives erythrosine [124] and RB [125,126], MB [125,127], Pcs [128,129], or ICG [130] for 
Figure 8. (a) Design of Ce6-containing pH-responsive polymeric nanoparticles for the treatment of
bacterial infections in slightly acidic media such as the urinary tract [117]. (b) Example of liposomal
formulation allowing both bacterial targeting via tuning of the surfactant proportions, and of the
photosensitisation properties via MB loading [118].
A potential downside of cationic liposomes is their easy fusion with mammalian cell membranes,
and the resulting damage. However, the modularity of the self-assembly strategy allows the combination
of amphiphilic building blocks with bacterial-specific targeting moieties. Thus, Yang et al. conjugated
an AMP (WLBU2) to the surface of temoporfin-loaded liposomes [119]. The low cost and simple
applicability of this formulation strategy offer great potential for clinical nano-medical applications.
In this sense, it is worth mentioning that the first clinical study using such a nano-medicine was reported
by Morgado et al. for the treatment of fungal infections [120]. Their AlPc-loaded nano-emulsion
allowed the treatment of onychomycosis without local or systemic side-effects.
3.2.2. Bio-Sourced Oligosaccharide Conjugates
In the world of NPs, bio-sourced macromolecules such as oligosaccharides represent a source
of well-documented readily available building blocks for the elaboration of stimulus-responsive
nano-syste s. Exploiting the properties (charge, supramolecular interactions, functionalisation, etc.)
of oligosaccharides has given rise to numerous examples of nano-PS for aPDT. Their preparation relies
either on covalent attachment of PS moieties, or encapsulation.
Chitosan is a bio-polymer obtained through deacetylation of chitin. Thanks to its intrinsic
poly-cationic nature, it has been reported to interact with the negatively charged phospholipids [121,122],
which provides it with a broad-spectrum antibacterial and antifungal action, including the prevention
of the development of biofilms [123]. Therefore, poly-cationic chitosan has been one of the most widely
utilised delivery and uptake increasing nano-carriers in aPDT.
Early examples of the potentiation of PDT by chitosan goes back to the 2000s, and it has since then
been used in co-administration, nano-formulations or covalent attachment of the xanthene derivatives
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erythrosine [124] and RB [125,126], MB [125,127], Pcs [128,129], or ICG [130] for antibacterial treatments
respectively with green to NIR light. Chitosan’s ability to disrupt and permeabilise biofilms is of key
importance in improving the efficiency of ROS.
Among the most recent applications of this strategy, Shrestha et al. tackled the major challenge of
dental infections [126]. In an effort to simultaneously eliminate persistent biofilms in root canals, as well
as reinforcing the damaged hard architecture of dentin, RB was covalently attached via carbodiimide
chemistry to chitosan NPs prepared by ionic gelation method with sodium tripolyphosphate (TPP)
(Figure 9). The resulting green-absorbing NPs were successfully demonstrated to be efficient in killing
biofilms of E. faecalis, where RB alone did not affect the multi-layered biofilm structure. In addition,
the photo-activation of the NPs triggered the crosslinking of collagen units in dentin, as well as the
incorporation of the chitosan particles within the matrix, which improved its toughness and mechanical
properties. Nevertheless, aggregation of the NPs and formation of toxic microparticles are potential
limitations of this work. Darabpour et al. later showed that the simple co-administration of chitosan
NPs prepared by an ionic gelation method along with 50 µM solutions of MB significantly reduced the
viability of S. aureus, MRSA, and P. aeruginosa biofilms in a synergistic manner upon irradiation [127].
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Figure 9. Examples of the preparation of chitosan nanoparticles (NPs) by ionic gelation for aPDT via
covalent surface attachment [127], encapsulation [130] or co-adminisation, [126] of different PS.
In an alternate strategy, the encapsulation of the PS inside chitosan NPs was reported by Corona
and co-workers [129]. Using the NPs as a delivery vehicle allowed them to counter the notorious
issues of solubility and aggregation of Pc dyes. Thus, a formulation of Myglyol®, chitosan and
chloroaluminium Pc led to positively charged 300 nm NPs that were activatable with 660 nm light,
which were effective in the treatment of S. mutans biofilms as chlorhexidine digluconates. Interestingly,
a series of ZnPc-chitosan covalent conjugates were also prepared for the treatment of fungal infections
by Tang et al. [128]. C albicans was killed with higher efficiency compared to the PS alone in every
case, regardless of the molecular weight of the chitosan derivative used, explained by the reduced
tendency to aggregation for the Pc derivative and a higher uptake by the fungi—especially into their
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mitochondria. Finally, the photodynamic treatment of bacterial biofilms was performed even deeper
into the phototherapeutic window in the work of Pourhajibagher et al. with the encapsulation of the
NIR absorbing dye ICG inside cationic chitosan [130]. Interestingly, their system resulted in a 91%
killing of A. actinomycetemcomitans and importantly reduction in biofilms upon irradiation at 810 nm,
but was also tested against periodontitis in combination with sonodynamic therapy [130,131].
Cyclodextrins (CDs) are oligosaccharides naturally produced by enzymatic conversion of starch.
Their macrocyclic toroidal shape and slightly hydrophobic cavity make them one of the most popular
building blocks in supramolecular chemistry and drug delivery. As such, α-, β- and γ-CDs have been
used for the preparation of PS-containing NPs, and in recent years porphyrins have been popular
dyes for this type of platform, being either covalently [132] or non-covalently bound to CDs [133–136].
The covalent strategy was used by Ribeiro et al. for the preparation of unsymmetrical Porphyrin-CD
conjugates [132], with thiopyridinyl-functionalised PS units cationised in order to improve the solubility
of the NPs and their affinity for bacterial membranes. In this study, it was reported that the conjugation
to CDs reduced slightly the affinity for Gram− bacteria compared to the PS alone, however the
enhanced solubility, availability, and singlet oxygen generation efficiency of the conjugates made them
a viable option for aPDT.
A host-guest strategy is often selected for its simplicity, as illustrated by the work of Zagami et al.
in which spherical NPs were prepared with quantitative entrapment efficiency by simple mixing
of the sulfonate-functionalised β-CD Captisol and the tetracationic TMPyP PS [135]. The same
building-blocks were recently applied in the preparation of nanorods by Khurana et al. [136] (Figure 10),
which showed decreased dark toxicity of the nano-PS compared to TMPyP. Interestingly, this simple
encapsulation strategy has also been used for PS-loaded textiles [134].
Molecules 2020, 25, 16 of 31 
Other types of sugar oligomers have been used, including cellulose with PpIX [139], or 
galactose 
[140] and maltoheptaose to improve the water solubility of the PS bis-iodo-BODIPY [141]. Although
the solubility and biocompatibility of the PS are usually enhanced, these oligosaccharides usually do
not have an active effect on microbial uptake or targeting, unless they are synthetically modified with
cationic groups [139,140] or a bacterial specific moiety [99]. In this sense, it is worth mentioning that
Le Guern et al. conjugated both Ce6 and the peptide PMX-B onto the surface of cellulose nanocrystals. 
The resulting construct was able to eradicate three strains of Gram− bacteria under white light
irradiation [99].
3.2.3. Synthetic and other Bio-Inspired Polymer Conjugates 
The conjugation of PS units to synthetic macromolecules offers a wide panel of possibilities. 
Once again, strategies are divided between a straightforward uptake increase triggered by poly-
cationic moieties, and the preparation of conjugates with a high level of specificity. 
Hyperbranched macromolecules and dendrimers offer interesting structural control options and 
versatility thanks to the possibility to conjugate or encapsulate. In this sense, Majoral’s phosphorous 
dendrimers have been adapted to PDT by incorporating known PS units and introducing cationic 
external layers [142,143]. Although their studies remained fundamental, the authors suggest that MB 
and RB can be linked to the dendrimers either via electrostatic interactions and π-stacking [142], or 
by covalent attachment [143]. Interestingly, the latest study revealed that the covalent RB-dendrimer 
conjugate possessed reduced photo-activity, presumably because of the structural modification of 
RB, thus impeding its use in aPDT and making the entrapment strategy a more attractive option. In 
a more applied study, Staegemann et al. prepared hyperbranched polyglycerols co-functionalised 
with a zinc porphyrin and with mannose units in order to target mannose receptors on the bacterial 
cell surface [144]. “Click chemistry” allowed covalent attachment of the modules onto the 
polyglycerol platform, while increased loadings of mannose promoted solubility and bacterial 
Figure 10. Examples of cyclodextrin derivatives used for the preparation of PS-containing NPs, either by
encapsulation of the PS units [136], or by encapsulation of an AMP acting as a bacterial-targeting
moiety [137].
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Targeting moieties can also be incorporated easily into the supramolecular edifice to improve
selectivity. In an elegant supramolecular self-assembly approach, Gao et al. reported an α-CD-Ce6
covalent conjugate in which the CD’s cavity encapsulated a PEG chain terminally functionalised with
the antimicrobial peptide Magainin I (M1) [137]. The host-guest complex could be assembled in a
micellar structure in which the M1 peptide, facing outwards, acts as the bacterial targeting moiety
(Figure 10). This feature allowed a 99.9999% killing efficiency against P. aeruginosa and MRSA biofilms
using red light. Moreover, thanks to the efficient targeting, the toxicity of the treatment proved less
than in the case of the α-CD–Ce6 conjugate alone. It is also worth mentioning that this approach was
adapted to fungal infections with the co-encapsulation of the non-water-soluble tetraphenylporphyrin
(TPP) PS and the antifungal agent fluconazole in β-CD [138].
Other types of sugar oligomers have been used, including cellulose with PpIX [139],
or galactose [140] and maltoheptaose to improve the water solubility of the PS bis-iodo-BODIPY [141].
Although the solubility and biocompatibility of the PS are usually enhanced, these oligosaccharides
usually do not have an active effect on microbial uptake or targeting, unless they are synthetically
modified with cationic groups [139,140] or a bacterial specific moiety [99]. In this sense, it is worth
mentioning that Le Guern et al. conjugated both Ce6 and the peptide PMX-B onto the surface of
cellulose nanocrystals. The resulting construct was able to eradicate three strains of Gram− bacteria
under white light irradiation [99].
3.2.3. Synthetic and other Bio-Inspired Polymer Conjugates
The conjugation of PS units to synthetic macromolecules offers a wide panel of possibilities.
Once again, strategies are divided between a straightforward uptake increase triggered by poly-cationic
moieties, and the preparation of conjugates with a high level of specificity.
Hyperbranched macromolecules and dendrimers offer interesting structural control options and
versatility thanks to the possibility to conjugate or encapsulate. In this sense, Majoral’s phosphorous
dendrimers have been adapted to PDT by incorporating known PS units and introducing cationic
external layers [142,143]. Although their studies remained fundamental, the authors suggest that MB
and RB can be linked to the dendrimers either via electrostatic interactions and π-stacking [142], or by
covalent attachment [143]. Interestingly, the latest study revealed that the covalent RB-dendrimer
conjugate possessed reduced photo-activity, presumably because of the structural modification of RB,
thus impeding its use in aPDT and making the entrapment strategy a more attractive option. In a
more applied study, Staegemann et al. prepared hyperbranched polyglycerols co-functionalised with
a zinc porphyrin and with mannose units in order to target mannose receptors on the bacterial cell
surface [144]. “Click chemistry” allowed covalent attachment of the modules onto the polyglycerol
platform, while increased loadings of mannose promoted solubility and bacterial selectivity (S. aureus).
Unfortunately, the addition of albumin to the culture quenched the aPDT effect which limits
clinical application.
Going beyond hyperbranched materials, reticulated networks of polymers can lead to carbon
nanoparticles (CNPs) or “nanodots” bearing specific chemical and photophysical properties dictated
partially by the building-blocks used in the crosslinking reaction. Such materials usually possess
intrinsic luminescent properties, and can sometimes be used as PS for aPDT when they present ROS
generation properties [145]. In order to create highly cationic CNPs for increased bacterial uptake,
Ning et al. performed hydrothermal treatment of a polyfunctional polyethylene-imine in the presence
of the dicarboxylate PpIX PS, thus yielding red-absorbing photoactive nano-objects in the 100 nm
range [146]. The hydrothermal treatment proved to be a simple procedure requiring no toxic solvents or
multi-step synthesis and retained the structure of the PS. However, as is often the case with poly-cationic
materials, these CNPs only provided efficient killing of Gram+ bacteria. Targeting capacities could
be improved either by surface coating with pathogen-specific units, or by direct modification of the
reagents used in the CNP synthesis. Interestingly, these strategies were exemplified by Sidhu et al.,
who achieved both the coating of standard citric acid-based CNPs with penicillin G, and the direct
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preparation of penicillin-based CNPs using the antibiotic as a carbon source [147] (Figure 11a),
which made the NPs intrinsically hostile towards pathogens with and without light. The use of
ampicillin as a carbon source in CNPs was also recently reported, and led to CNPs killing preferentially
Gram+ bacteria with ROS generation under visible light irradiation [148]. In addition, by using
appropriate building blocks, either in the core or on the surface, the ROS generation efficiency could be
fine-tuned by Mandal et al., whose CNPs were derived from anthraquinone derivatives. These could
be rendered more photo-toxic by coating the surface of the NP with BSA [149] which results in a
reduction of the band gap in the CNPs as evidenced by a red-shifted absorption spectrum, while the
creation of more electron–hole pairs leads to increased ROS generation. Moreover, loading these
CNP-BSA conjugates with ciprofloxacin led to a dramatic increase in bactericidal efficiency thanks to a
synergistic effect between the antibiotic and the ROS.
Bacteria produce a variety of EPS creating a binding network between pathogens. As such,
the specificity of this macromolecular substance makes it an inspiration for highly targeted aPDT,
and recently, this type of bacterial-targeting biopolymers have been conjugated to appropriate PS.
Li et al. thus tagged bacterial exopolysaccharides extracted from Lactobacillus plantarum with an anionic
RB photosensitizer to prepare bacterial-targeting self-assembling nanoparticles [150]. These NPs
possessed an increased singlet oxygen generation capacity compared to RB in solution, improving their
killing efficiency for both Gram− and Gram+ bacteria. Qi et al. inspired by the production of EPS,
introduced bacteria into an atom transfer radical polymerisation (ATRP) reaction to create templated
polymers [151]. The specific sequence of methacrylate monomers in the templated polymer was
dictated by their interactions with the bacterial cell wall/membrane, and thus specific to the bacterial
strain used. Using a triphenylamine-pyridinium-containing monomer, the templated polymer could
not only generate fluorescence by AIEE, but also generate ROS to induce specific bacterial killing
under white light irradiation (Figure 11b). This biomimetic strategy could be extended successfully to
drug-resistant and clinical strains of Gram− bacteria due to their particular surface components.
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3.2.4. Hybrid and Inorganic Nanoparticles
Because of their unique electronic, physical and morphological properties, as well as their
possible arrangement into core-shell hybrid structures, inorganic NPs provide boundless versatility
and opportunity for biomedical applications. Numerous examples of the conjugation of PS to inorganic
or hybrid NPs for aPDT have been reported, however, only a few numbers of them have claimed
active pathogen targeting in recent years. Silica and gold NPs are typically employed as nano-carriers,
while other materials such as silver and carbon nanotubes have been exploited for their intrinsic
antimicrobial properties.
In the first category, Zhao et al. reported a way to enhance the affinity of Ce6-loaded silica NPs
for bacterial membranes by using a poly(allylamine) hydrochloride coating [152]. The design of their
nano-system was such that the Ce6 units self-aggregate on the NPs in solution, thus quenching both
the emission and singlet oxygen generation properties of the excited state. Upon binding of the cationic
coating onto the bacteria, the aggregation state of Ce6 becomes modified, which restores its luminescence
and photo-toxicity. This self-activation silica nano-PS allowed complete elimination of MRSA.
Nonell and co-workers also reported amino-functionalised mesoporous silica NPs, and co-decorated
them with mannose units for additional targeting [153]. MB was adsorbed in the pores of the NPs for
aPDT with red-light. In accordance with previous reports, the dark toxicity of the dye was reduced,
and in P. aeruginosa, the mannose units increased the efficiency of the nano-system compared to the
amino-functionalised NPs (Figure 12a). To further potentiate IR-light-mediated aPDT, Grüner et al.
designed core–shell NPs also based on mesoporous silica further coated with NaYF4:Yb:Er to exploit
energy up-conversion towards the visible [154]. The upconverted energy is then transferred to SiPc
loaded in the NPs to generate 1O2*, while different cationic and anionic coatings allowed comparison
of bacterial uptake. As expected, positively charged NPs showed the highest bactericidal efficiency,
however, a certain dark toxicity was observed in Gram− bacteria.
Being renowned for its low toxicity, gold has also been used as a platform for targeted aPDT.
Exploiting a multifunctional nano-system also used commonly in sensors [155,156], Khan et al.
used mannose-based Dextran to cap gold NPs (AuNPs) and aggregate them with Concanavalin-A
(ConA), a lectin derivative able to bind mannose and glucose residues in LPS [157]. As a major
component of the outer membrane of Gram-negative bacteria, LPS are important markers to consider
to increase specificity, and this Dextran-ConA dual-targeting system allowed specific attachment
to the fimbriae and to the LPS of bacteria. The resulting AuNPs were loaded with the clinically
approved PS MB, which resulted in the effective killing of MDR clinical strains of E. coli, K. pneumoniae
and E. cloacae. Interestingly, enhanced singlet oxygen generation was reported in this nano-system
thanks to a monomeric arrangement of the MB, which, conversely to the MB liposomes developed by
Boccalini et al. [118], favours a type-II photophysical mechanism.
Other types of inorganic nanomaterials have been reported to intrinsically possess certain levels of
antimicrobial activity. The bactericidal power of silver has been known since antiquity [158], and recently
carbon nanomaterials have also been suggested as potential antibacterial agents [159]. Used as a
nano-platform for PS, such materials can give rise to photoactive NPs whose core naturally interacts
with pathogens and/or acts in synergy with the photodynamic mediated killing. This synergistic effect
has recently been evidenced by Shitomi et al. in RB-containing silver nanoclusters [160]. The 1O2*
generated by RB upon white light irradiation combines with Ag+ ions release to kill S. mutans in
a more efficient way than either alone, while the antibacterial activity of the clusters was reported
to be maintained even after irradiation thanks to the released ions (Figure 12,b). Other AgNPs-MB
electrostatic conjugates reported by Parasuraman et al. inactivated P. aeruginosa and S. aureus with
enhanced efficiency compared to MB alone, and without significant dark activity [161]. Interestingly,
the AgNPs were prepared by bacteria-mediated synthesis, and the biogenic AgNPs enhanced the
uptake of MB by pathogenic strains.
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Figure 12. (a) Comparison of the bacterial specificity reported for amino- and mannose-functionalised
MB-loaded mesoporous silica NPs for aPDT treatment of P. aeruginosa [153]; (b) Bactericidal modes of
action of (RB)-containing silver nano-clusters during and after light irradiation [160].
A similar strategy was applied with single- and multi-wall carbon nanotubes (SWCNTs and
MWCNTs) due to their potent interactions with bacteria and their large surface areas. In one approach,
Sah et al. used carboxylic acid-modified SWCNTs as a platform for attachment of amino functionalised
tetraphenylporphyrin (TPP) photosensitizers [162] and used this system against S. aureus. Non-covalent
encapsulation of TBO and MB dyes in MWCNTs was reported by Busi and co-workers [163,164].
Carbon nanographene oxide is another typical carbon material that has been applied in this strategy,
and was used as a vehicle for NIR absorbing ICG [165]. The latest system proved to be 1.3 times more
efficient than ICG alone against E. faecalis in the treatment of endodontic infections. The drawbacks of
this strategy reside in the absence of microbial targeting and potential dark toxicity or side-effects.
Remarkably, coated multifunctional NPs exploiting the properties of different materials can also
be prepared. As such, a theranostic nano-system integrating both surface-enhanced Raman scattering
(SERS) and aPDT was elaborated by Zhou et al. [166]. Silver-coated AuNPs served as a SERS-active core
material for diagnostic purposes, and were further encapsulated in silica. Further conjugation of this
material with a NIR-absorbing naphthalocyanine PS, and covalent attachment of vancomycin enabled
highly efficient imaging and treatment of vancomycin-resistant bacterial strains, including in mice
models. Finally, vancomycin was given a dual role in a slightly different approach by Zou et al. [167].
The reducing properties of vancomycin allowed the one-pot preparation of CuS nanocomposites in
which the antibiotic was also used as a Gram+ targeting agent. The strong NIR photo-activity of the
copper core allows synergistic photodynamic and photothermal killing of resistant Gram+ bacteria.
This novel antibacterial photo-material was also tested with success against vancomycin-resistant
strains of bacteria in mice infection models.
3.2.5. Immunoconjugates and Protein Conjugates
High molecular weight bio-macromolecules such as antibodies or proteins can sometimes be
used as a platform for PDT drugs, and potentially increase the level of specificity. Immunoconjugates
prepared by the combination of specific antibodies with drugs have been used in aPDT since the early
1990s [168–170]. As such, Protein A, expressed in the bacterial cell wall of S. aureus has been a target of
choice in this field, opening up new ways for the treatment of MRSA infections [41,170]. The selective
lethal photosensitization of S. aureus [170] and MRSA [41] was reported by conjugating chlorins
and bacteriochlorins to immunoglobulin G (IgG). An alternative targeting strategy was reported by
Suci et al. [171]. Their research focused on a viral protein cage modified at reactive cysteines as an
attachment point for a ruthenium-based PS. The resulting NPs were further modified with poly-lysine
for non-specific bacterial targeting, and with a monoclonal antibody specific to protein A. With this
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nano-platform, the authors claimed that the delivery of PS per binding event was 45 times higher
than in the case of a PS-IgG immunoconjugate. A Ce6 immunoconjugate was also used for whole
blood bacterial inactivation by Kim et al. [172]. The red-absorbing PS was conjugated to a polyclonal
antibody to S. aureus and to a penicillin-binding protein 2a monoclonal antibody for MRSA treatment.
The compounds were photo-activated within a thin transparent tube allowing ample and efficient
illumination with 83 to 99.9% of bacteria successfully killed without significant off-target damage or
changes in red blood cell number. The main drawback of the immunoconjugate strategy is usually the
cost of the targeting ligands, which will render the treatment expensive and less clinically relevant in
developing countries.
Regarding protein conjugates, Cantelli et al. recently used carbodiimide chemistry to randomly
conjugate RB to the homo-tetrameric lectin ConA [173] with an average addition of 2.4 PS per targeting
ligand, and a 10-fold higher superoxide generation compared to the model compound. With improved
recognition of LPS in the Gram− bacterial membrane, it showed a 4.5-fold higher uptake and greater
photodynamic effect. The enhanced targeting of Gram− bacteria by this conjugate improved, up to
117-fold, the bacterial killing of planktonic E. coli compared to RB alone. The self-assembly of a
tetraphenylethylene-based organoplatinum(II) metallacycle with the coat protein of tobacco virus,
conjugated by click chemistry to a transacting activator of transduction (TAT) peptide, was also
reported by Gao et al. [174]. The TAT peptide drives internalisation, enhancing the aPDT effect against
Gram− bacteria in particular, while the use of this platinum-based PS provided both AIEE properties
and enhanced ROS generation via the heavy atom effect. It is also interesting to note that some
proteins exhibit naturally ROS generation properties, which opens new treatment perspectives for the
future [175,176].
4. Conclusions and Perspectives
Because no resistance mechanism to singlet oxygen or ROS has been reported, nor would be
expected to arise due to their multi-faceted and generic killing mechanisms, targeted aPDT offers a novel
and viable alternative in an era where antibiotics may no longer be long-term options. Nonetheless,
translating the potential of aPDT dyes into patients requires considerable efforts, in particular, it is
crucial to diminish off-target damage to healthy cells.
The correct selection of a targeting moiety to combine with an aPDT dye is the first step in this
direction. As presented in this review, a wide panel of covalent, non-covalent, supramolecular and
nano-based strategies are available in the scientists’ toolbox to reach this goal, and the examples
reported over the past half-decade hold great promise for the future. However, in spite of its great
potential, the widespread use of aPDT in clinics could be hampered by the lack of point-of-care devices
for irradiation and treatment of localised infections. Thus the development of clinically relevant
user-friendly light-emitting devices [177,178], such as portable light sources or optical fibers, is also of
utmost importance in order to adapt the treatment to both superficial and internal infections. Therefore,
transdisciplinary research is the key to future breakthroughs in the field.
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